Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics has secured a follow-on contract with Aptatek Biosciences to advance the development of an in-home monitoring device for phenylketonuria (PKU), a rare genetic disorder. The contract, valued at $1.5 million, will see Lumos enhance the device’s design and conduct verification studies, with the project expected to commence in September 2025. This collaboration underscores Lumos’ expertise in diagnostic technologies and its role in potentially transforming PKU management, offering significant implications for patients and stakeholders in the healthcare sector.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The company offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms, focusing on infectious and inflammatory diseases.
Average Trading Volume: 6,420,680
Technical Sentiment Signal: Buy
Current Market Cap: A$94.19M
For an in-depth examination of LDX stock, go to TipRanks’ Overview page.